ESCRS - FPM10.05 - Corneal Crosslinking With Riboflavin And Uva Light In Progressive Keratoconus: Fifteen-Year Results.

Corneal Crosslinking With Riboflavin And Uva Light In Progressive Keratoconus: Fifteen-Year Results.

Published 2022 - 40th Congress of the ESCRS

Reference: FPM10.05 | Type: Free paper | DOI: 10.82333/6vnv-r312

Authors: Frederik Raiskup* 1 , Robert Herber 1 , Eberhard Spoerl 1

1DEPT. OF OPHTHALMOLOGY, C. G. CARUS UNIVERSITY HOSPITAL DRESDEN,Dresden,Germany

Purpose

To analyze the 15-year results of corneal crosslinking (CXL) in progressive keratoconus.

Setting

Department of Ophthalmology, Carl Gustav Carus University Hospital, TU Dresden, Germany

Methods

This retrospective study included keratoconic eyes with progressive disease course treated from 2002 to 2006. CXL was performed by applying riboflavin and UVA light according standard protocol. The corrected distance visual acuity (CDVA), slit-lamp examination and corneal topography as well as corneal thickness values were recorded preoperatively and 15 years after the treatment.

Results

The study enrolled 36 patients (47 eyes). The mean age of the patients was 26.9±7.4 years at the baseline and the mean follow-up, 15.4±1.8 years. The mean apical keratometry (Kapex) value was 61.6 diopters preoperatively and 55.1 diopters postoperatively; the decrease was statistically significant (P<0.001). The mean steep K (Ksteep) value was 53.5 diopters preoperatively and 49.4 diopters postoperatively; the mean flat K (Kflat) value was 47.1 diopters preoperatively and 45.7 diopters postoperatively. The decrease of these values were also statistically significant (P<0.001).The postoperative CDVA improved statistically significantly from 0.4 logMAR preoperatively to 0.2 logMAR after the treatment.

Conclusions

CXL was effective in treating keratoconic eyes in progressive stage of the disease, achieving long-term stabilization of the ectatic condition.